Tomimoto, H., Kondo, T., Sunada, Y., Ishikawa, H., Shindo, A., Izumi, Y., . . . Uchikawa, O. Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: Randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations. BMJ Publishing Group.
Chicago Style (17th ed.) CitationTomimoto, Hidekazu, et al. Repurposing Bromocriptine for Aβ Metabolism in Alzheimer’s Disease (REBRAnD) Study: Randomised Placebo-controlled Double-blind Comparative Trial and Open-label Extension Trial to Investigate the Safety and Efficacy of Bromocriptine in Alzheimer’s Disease with Presenilin 1 (PSEN1) Mutations. BMJ Publishing Group.
MLA (9th ed.) CitationTomimoto, Hidekazu, et al. Repurposing Bromocriptine for Aβ Metabolism in Alzheimer’s Disease (REBRAnD) Study: Randomised Placebo-controlled Double-blind Comparative Trial and Open-label Extension Trial to Investigate the Safety and Efficacy of Bromocriptine in Alzheimer’s Disease with Presenilin 1 (PSEN1) Mutations. BMJ Publishing Group.